For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is ending that holdout with the proposed $1.5 billion deal for Myricx.
Source: FierceBiotech
